News

Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.

Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.

A content analysis of 159 picture books found food often symbolized family connection and culture more than nutrition alone, according to Carol Duh-Leong, MD, MPP.

The FDA approved zilganersen (Zanvastro) for Alexander disease in patients from infancy through adulthood, based on Phase 1-3 gait speed data.

New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.

CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.

The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.

Can you guess the diagnosis?

AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.

Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.

Take a quick look at everything you may have missed in August, including the top FDA approvals and latest clinical updates.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.

Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.

A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.

Back-to-school visits close vaccine gaps fast—MMR, Tdap, meningococcal, HPV, plus flu/RSV prevention before illnesses surge.

Can you guess the diagnosis?

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Bradley Peterson, MD, discusses when pediatricians should consider adding a second treatment for pediatric anxiety and why improvement may continue well beyond the first 3 months of therapy.

The AAP's updated clinical report revises screening timelines, ferritin thresholds, and treatment protocols for pediatric iron deficiency and iron deficiency anemia.

CDC has declared the Nara Organics infant botulism outbreak over; genetic testing ties it to the 2025 ByHeart outbreak.

Bradley Peterson, MD, discusses how treatment preferences, access, tolerability, and patient characteristics can guide pediatric anxiety care when CBT and medication provide similar overall benefits.

Lori Handy, MD, says vaccine conversations with hesitant families should prioritize trust, follow-up, and the benefits for the individual child.

CBT and fluoxetine both reduced pediatric anxiety, while starting with CBT before adding medication showed advantages on several outcomes.

The FDA has approved Tivicay PD (dolutegravir) to treat HIV-1 in newborns from birth, based on IMPAACT 2023 pharmacokinetic and safety data.

FDA De Novo authorization establishes Avulux lenses as an option for migraine-associated light sensitivity in patients aged 12 years and older.

FDA authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks glucose and ketones, for patients 2 and older with diabetes.

FDA approved nipocalimab (Imaavy) for wAIHA in patients 12 and older, based on Phase 2/3 ENERGY trial data on durable hemoglobin response.

Nine societies outline 6 domains of hospital-level sepsis strategies, from rapid blood culture diagnostics to daily toothbrushing protocols.